Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.
Osteosarcoma is the most frequent primary bone tumor and occurs mainly in young patients (average age: 18 years). No evolution of the survival rates has been recorded for two decades in response to current treatment, associating often toxic and badly tolerated cures of chemotherapy (given a significant rate of bad responders) with preserving surgery. Among the proposed innovative strategies, immune-based therapy, antiangiogenesis agents, tumor-suppressor or suicide gene therapy, or anticancer drugs not commonly used in osteosarcoma are presented. A further strategy is to target the tumor microenvironment rather than the tumor itself.
Lamoureux
François
F
Université de Nantes, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculté de Médecine, Nantes cedex 1, France. francois.lamoureux@univ-nantes.fr
Trichet
Valérie
V
Chipoy
Céline
C
Blanchard
Frédéric
F
Gouin
François
F
Redini
Françoise
F
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D019468:Disease Management; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D012516:Osteosarcoma / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents